Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Mol Psychiatry ; 21(12): 1733-1739, 2016 12.
Artigo em Inglês | MEDLINE | ID: mdl-26976039

RESUMO

Maladaptive glucocorticoid effects contribute to stress-related psychopathology. The glucocorticoid receptor (GR) that mediates many of these effects uses multiple signaling pathways. We have tested the hypothesis that manipulation of downstream factors ('coregulators') can abrogate potentially maladaptive GR-mediated effects on fear-motivated behavior that are linked to corticotropin releasing hormone (CRH). For this purpose the expression ratio of two splice variants of steroid receptor coactivator-1 (SRC-1) was altered via antisense-mediated 'exon-skipping' in the central amygdala of the mouse brain. We observed that a change in splicing towards the repressive isoform SRC-1a strongly reduced glucocorticoid-induced responsiveness of Crh mRNA expression and increased methylation of the Crh promoter. The transcriptional GR target gene Fkbp5 remained responsive to glucocorticoids, indicating gene specificity of the effect. The shift of the SRC-1 splice variants altered glucocorticoid-dependent exploratory behavior and attenuated consolidation of contextual fear memory. In conclusion, our findings demonstrate that manipulation of GR signaling pathways related to the Crh gene can selectively diminish potentially maladaptive effects of glucocorticoids.


Assuntos
Hormônio Liberador da Corticotropina/metabolismo , Coativador 1 de Receptor Nuclear/metabolismo , Processamento Alternativo , Tonsila do Cerebelo , Animais , Corticosterona/metabolismo , Medo , Regulação da Expressão Gênica/efeitos dos fármacos , Glucocorticoides/metabolismo , Camundongos , Coativador 1 de Receptor Nuclear/genética , Regiões Promotoras Genéticas/efeitos dos fármacos , Isoformas de Proteínas/genética , Isoformas de RNA , RNA Mensageiro/metabolismo , Receptores de Glucocorticoides/metabolismo , Receptores de Esteroides , Proteínas de Ligação a Tacrolimo/metabolismo
2.
AIDS ; 15(18): 2423-9, 2001 Dec 07.
Artigo em Inglês | MEDLINE | ID: mdl-11740193

RESUMO

OBJECTIVES: To determine the effect of adjuvant prednisolone use on the development of abacavir (ABC)- and nevirapine (NVP)-associated hypersensitivity reactions (HSR). METHODS: Randomized open-label study in antiretroviral-naive adult HIV-1 infected patients using a factorial design in which NVP and/or hydroxyurea (HU) and/or prednisolone are added to a regimen of ABC, zidovudine and lamivudine. Prednisolone (40 mg once daily) was added for the first 2 weeks of treatment. As it was difficult to distinguish ABC-associated HSR from NVP-associated HSR, these events were treated as a composite endpoint. The odds ratio (OR) of developing HSR for prednisolone-use was calculated with and without stratification by NVP and/or HU. Logistic regression was performed to identify risk factors for developing HSR. RESULTS: Of the 229 patients 115 were randomized to prednisolone and 114 to no-prednisolone; 19 (17%) and 11 (10%) patients, respectively, developed HSR. The expected prevention of HSR by prednisolone use was not observed. In fact use of prednisolone showed an increased risk for HSR although this did not reach statistical significance [OR, 1.82; 95% confidence interval (CI), 0.82-4.03]. There was a higher incidence of HSR in the NVP group than in the non-NVP group (20% versus 6%; P = 0.002). An additional risk factor identified in a multivariate logistic model was a high baseline CD4 cell count (OR, 1.26 per 100 x 10(6) cells/l increase; 95% CI, 1.06-1.51). CONCLUSIONS: The simultaneous start of ABC and NVP in first-line antiretroviral regimens should be avoided because of a high (20%) incidence of HSR. Short-term therapy with prednisolone did not prevent HSR in patients using ABC with or without NVP.


Assuntos
Fármacos Anti-HIV/efeitos adversos , Didesoxinucleosídeos/efeitos adversos , Hipersensibilidade a Drogas/prevenção & controle , Infecções por HIV/tratamento farmacológico , Nevirapina/efeitos adversos , Prednisolona/uso terapêutico , Adulto , Fármacos Anti-HIV/uso terapêutico , Anti-Inflamatórios/uso terapêutico , Didesoxinucleosídeos/uso terapêutico , Feminino , HIV-1 , Humanos , Masculino , Pessoa de Meia-Idade , Nevirapina/uso terapêutico , Inibidores da Transcriptase Reversa/efeitos adversos , Inibidores da Transcriptase Reversa/uso terapêutico
3.
Eur J Clin Nutr ; 47(11): 815-9, 1993 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-8287852

RESUMO

This study examined whether drinking of water with breakfast affects the feelings of satiety and hunger, and how long after the meal this effect is maintained. Eight healthy, normal-weight women had three breakfasts with two extra glasses (4 dl) of water and three similar breakfasts without water. The breakfasts were served on three successive mornings during a 2 week period. The subjects filled in forms with visual analogue scales on feelings of hunger, satiety and desire to eat. The forms were filled just before the breakfast, in the middle of the breakfast before and after drinking of water, after finishing the meal, and thereafter every 30 min until 11.15 a.m. The results show that drinking two glasses of water affects subjective feelings of hunger and satiety during the meal, but this effect is not maintained after the meal. It is suggested that during a meal subjective feelings of hunger and satiety change independently of the food energy consumed. This study allows, however, no conclusions on the possible influence of drinking water on actual food intake during and after a meal.


Assuntos
Ingestão de Líquidos/fisiologia , Ingestão de Alimentos/fisiologia , Fome , Saciação , Adulto , Ingestão de Energia , Feminino , Humanos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA